5 Best European Growth Stocks to Buy

3. CRISPR Therapeutics AG (NASDAQ:CRSP)

On May 13, 2026, Bernstein raised the firm’s price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $56 from $50 while maintaining a Market Perform rating on the shares. Bernstein said the biotech sector has started 2026 strongly, with the group up 11% year-to-date and outperforming both large-cap pharma and the broader S&P 500. The firm added that smaller biotech companies have led the rally and maintained a constructive view on the sector, citing expectations for continued healthy M&A and IPO activity alongside recent FDA leadership changes that could benefit earlier-stage biotech companies.

Meanwhile, BofA lowered the firm’s price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $83 from $86 while maintaining a Buy rating on the shares. The firm said it came away from the company’s first-quarter updates with “few changes to the core thesis,” describing the overall developments as encouraging.

On May 4, 2026, CRISPR Therapeutics AG (NASDAQ:CRSP) reported that first-quarter revenue totaled $1.4M. Chairman and CEO Samarth Kulkarni said the quarter reflected continued execution across the company’s broader gene-editing platform. Kulkarni highlighted the expansion of zugo-cel into additional autoimmune disease indications and continued progress advancing several in vivo liver-directed programs toward clinical development. The company also pointed to continued momentum for CASGEVY. Management added that with a strengthened balance sheet and multiple upcoming catalysts, 2026 could become a defining year for the company.

CRISPR Therapeutics AG (NASDAQ:CRSP) develops gene-editing therapies for serious diseases using its CRISPR/Cas9 platform technology.